Bengaluru-based Healthify has completed an all-stock merger with US-based Berry Street to scale its AI-driven metabolic health platform in the American market. The deal integrates Healthify’s AI assistant, Ria, with Berry Street’s 2,000-strong dietitian network to manage US insurance billing. The new entity aims to capture the growing demand for GLP-1 weight-management care, though readers should note the company remains private and faces complex integration and regulatory risks.
Bengaluru-based Healthify has announced an all-stock merger with US-based Berry Street. The deal is designed to combine Healthify’s proprietary AI-led nutrition tools with the US company’s established insurance and clinical infrastructure. While Healthify maintains a significant presence in India, it is important to note that the company is not a publicly listed firm on the NSE or BSE.
This merger aims to solve a primary barrier for digital health firms attempting to enter the US market: complex insurance reimbursement. Healthify’s AI assistant, known as Ria, provides nutrition coaching and tracking. However, to operate effectively in the US, the firm needs the administrative backbone that Berry Street provides. Berry Street handles insurance credentialing and billing services, allowing the combined platform to link Healthify’s AI-driven insights with a network of over 2,000 registered dietitians across all 50 US states.
The strategic focus of this partnership is the rising demand for weight-management services, particularly for patients using GLP-1 anti-obesity medications. By creating a model that combines daily AI guidance with insurance-covered clinical intervention, the company aims to become a standard platform for long-term metabolic health management.
Regarding the operational structure, the firm will be led by co-CEOs Tushar Vashisht, the founder of Healthify, and Noah Kotlove, the founder of Berry Street. Tushar Vashisht will focus on global expansion and AI development, while Noah Kotlove will oversee US operations. The combined entity will retain the Berry Street brand for its US business, while the Healthify name will continue to be used in its other international markets.
From a risk perspective, this deal involves significant operational challenges. Successfully merging an AI-first consumer application with a clinical, insurance-linked service model is complex. Additionally, the business model is highly sensitive to US healthcare regulations. Because the service is built around supporting patients on GLP-1 medications, any major changes in insurance reimbursement policies or government regulations regarding these drugs could impact the company’s revenue potential. The firm also operates in a competitive space, facing pressure from other established digital health providers attempting to capture the same market segment. Since the company is private, investors do not have a direct way to participate in its equity, and the long-term success of the merger will depend on how effectively the management team integrates these two distinct business models.